echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Thirteen pharmaceutical stocks are worth hundreds of billions of dollars, including PD-1 single-head players.

    Thirteen pharmaceutical stocks are worth hundreds of billions of dollars, including PD-1 single-head players.

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network Industry Dynamics, according to industry statistics, as of July 15, the Value of the A stock market to break 100 billion pharmaceutical stocks once again a new high, reached 13These 13 enterprises cover innovative drugs, medical devices, medical services, Chinese medicine, vaccines and other sub-sectors, of which vaccine enterprises accounted for 4 seatsBased on the market capitalization of 13 companies, Hengrui Pharmaceuticals has a market capitalization of 543.9 billion yuan, far outpacing that of other pharmaceutical companies, and as of July 15, Hengrui Pharma's share price was 102.25 yuanIndustry pointed out that if Hengrui Pharmaceuticals can also be regarded as a technology stocks, then the current total market value of technology stocks is 500 billion yuanHengrui Pharmaceuticals is a pharmaceutical and health company engaged in pharmaceutical innovation and high-quality drug research and development, the company was listed on the Shanghai Stock Exchange in 2000In 2019, the company achieved revenue of more than 23 billion yuan and tax revenue of 2.4 billion yuanIn Forbes' 2020 list of the World's Top 2000 Listed Companies, Hengrui Pharma ranked 1,066th, up 147 places from 2019Murray Medical and Drug Mingkant followedMeirui Pharma ranked second with a market capitalization of $419.8 billion, with a share price of $34.629 billion as of July 15In addition, the market value of the drug Ming Kang ranked third, as of July 15 reached 244.8 billion yuan, the share price of 105.99 yuanIt is worth noting that among the 13 pharmaceutical companies with a market capitalisation of more than 100 billion yuan, the company's market capitalization reached 131.7 billion yuan, including Junshi Bio, which landed on the Company's board on July 15Data show that Junshi biological is the first company from the new three boards to the science and technology board, at the same time listed on the Hong Kong Stock ExchangeData show that Junshi Bio was founded in December 2012, the company has been listed in the new three board tradingIn April 2018, the new three boards and the Hong Kong Stock Exchange signed a memorandum of understanding on cooperation, mutual acceptance of qualified companies to apply for listing, listing, Junshi Bio is the first company under the memorandum to "unprofitable companies" landing on the HKEx enterprisesIn September 2019, Junshi Bio's application for listing in the company was acceptedIn May this year, the IPO application registration took effect, June 30, issued a notice to determine the price of the issue of 55.50 yuan per shareAt present, Junshi biological products in the research has 21, but only PD-1 antibody Trepri mono-resistance one product on the market On December 17, 2018, Trepri Single Resistance was approved for sale, becoming the first domestic anti-PD-1 monoantida approved In 2019, The Ripley Single Resistance brought in 774 million yuan in revenue for Junshi Bio It is reported that Thepristain has carried out more than 30 clinical studies in the world, including 15 key registered clinical studies, covering nasopharyngeal cancer, urinary skin cancer, lung cancer, stomach cancer, esophageal cancer, liver cancer, kidney cancer and other indications, in the first half of this year, the product also submitted in the domestic nasopharyngeal cancer and urinary tract skin cancer two new adaptation applications and acceptance In addition, this year landed in the A-share pharmaceutical enterprises, the bright "new star" has two, respectively, Wantai Biological and Gan li Pharmaceuticals Among them, Wantai Bio's main business for in vitro diagnostics and vaccines On April 29, Wantai Bio landed on the main board of the Shanghai Stock Exchange, the issue price of 8.75 yuan, after the listing, Wantai Bio appeared more than 20 times On July 14, The market value of Wantai Bio reached 101.896 billion yuan, but the next day opened, the funds sold a large amount, at one point a rapid decline, the market value fell back to 100 billion below, at 93.71 billion Gan Li Pharmaceuticals' performance appeared to be even stronger, on June 29th, Gan Li Pharmaceuticals successfully listed on the Shanghai Stock Exchange, and now has a market value of 100 billion yuan, July 15 daily 114.8 billion yuan, sitting in the position of "insulin leader shares." However, because Gan Li Pharmaceuticals has not yet opened the board, so the next will usher in how many ups and downs still need time to prove  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.